Compare ARDX & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | ICFI |
|---|---|---|
| Founded | 2007 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2014 | 2006 |
| Metric | ARDX | ICFI |
|---|---|---|
| Price | $7.32 | $87.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $12.95 | ★ $99.25 |
| AVG Volume (30 Days) | ★ 5.9M | 129.7K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 0.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.30 |
| Revenue | $398,234,000.00 | ★ $1,925,502,000.00 |
| Revenue This Year | $22.44 | N/A |
| Revenue Next Year | $34.00 | $2.52 |
| P/E Ratio | ★ N/A | $16.66 |
| Revenue Growth | ★ 58.12 | N/A |
| 52 Week Low | $3.21 | $72.03 |
| 52 Week High | $8.40 | $117.71 |
| Indicator | ARDX | ICFI |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 45.22 |
| Support Level | $6.92 | $87.93 |
| Resistance Level | $8.02 | $94.40 |
| Average True Range (ATR) | 0.41 | 2.72 |
| MACD | -0.13 | -0.99 |
| Stochastic Oscillator | 17.31 | 13.10 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.